The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Clinical Characteristics and Prognosis of Hepatocellular Carcinoma: Analysis Based on Serum Alpha-fetoprotein Levels
Abstract
The purpose of this study was to determine whether a relation does exist between clinicopathologic features and the prognosis of hepatocellular carcinoma (HCC) with respect to serum alpha-fetoprotein (AFP) levels at diagnosis. We reviewed the clinical data of 309 pathologically proven HCC cases divided into three groups: group 1 with normal AFP (<20 IU/mL), group 2 with moderately elevated AFP (20-399 IU/mL) and group 3 with markedly elevated AFP (> or =400 IU/mL). Of these, there were 76 (24.6%), 78 (25.2%), and 155 patients (50.2%) in groups 1, 2, and 3, respectively. We found that HCC patients with high AFP tended to have greater tumor size, bilobar involvement, massive or diffuse types, and portal vein thrombosis. Nonetheless, we could not establish a correlation between increased AFP and Okuda's stages, degree of tumor differentiation, or extrahepatic metastasis. The median survival rates in groups 1 (6 months) and 2 (7 months) were significantly longer than that of group 3 (3 months). On multivariate logistic regression analysis, positive hepatitis B surface antigen (HBsAg) status and bilobar tumor involvement represented the independent factors for predicting high AFP values. We concluded that AFP is useful not only for diagnosis, but also as a prognostic indicator in patients with HCC . However, it cannot be considered a sensitive tumor marker, particularly during the early stages in HBsAg-negative patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS
Beasley, R. P., Lin, C.-C., Hwang, L.-Y., & Chien, C.-S. (1981) · The Lancet · doi:10.1016/s0140-6736(81)90585-7 · Cited by 2,865
Okuda, K., Ohtsuki, T., Obata, H., Tomimatsu, M., Okazaki, N., Hasegawa, H., Nakajima, Y., & Ohnishi, K. (1985) · Cancer · doi:10.1002/1097-0142(19850815)56:4<918::aid-cncr2820560437>3.0.co;2-e · Cited by 1,931
Des-γ-Carboxy (Abnormal) Prothrombin as a Serum Marker of Primary Hepatocellular Carcinoma
Liebman, H. A., Furie, B. C., Tong, M. J., Blanchard, R. A., Lo, K.-J., Lee, S.-D., Coleman, M. S., & Furie, B. (1984) · New England Journal of Medicine · doi:10.1056/nejm198405313102204 · Cited by 617
DI BISCEGLIE, A. M., RUSTGI, V. K., HOOFNAGLE, J. H., DUSHEIKO, G. M., & LOTZE, M. T. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-390 · Cited by 454
Early Recognition of Hepatocellular Carcinoma Based on Altered Profiles of Alpha-Fetoprotein
Sato, Y., Nakata, K., Kato, Y., Shima, M., Ishii, N., Koji, T., Taketa, K., Endo, Y., & Nagataki, S. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306243282502 · Cited by 439
Screening for hepatocellular carcinoma
Collier, J., & Sherman, M. (1998) · Hepatology · doi:10.1002/hep.510270140 · Cited by 425
Hepatic Resection for Hepatocellular Carcinoma An Audit of 343 Patients
Lai, E. C. S., Fan, S.-T., Lo, C.-M., Chu, K.-M., Liu, C.-L., & Wong, J. (1995) · Annals of Surgery · doi:10.1097/00000658-199503000-00012 · Cited by 400
Early Recognition of Hepatocellular Carcinoma Based on Altered Profiles of Alpha-Fetoprotein
&NA; (1994) · Journal of Occupational and Environmental Medicine · doi:10.1097/00043764-199412000-00009 · Cited by 356
Hepatocellular carcinoma in the United States: Prognostic features, treatment outcome, and survival
Stuart, K. E., Anand, A. J., & Jenkins, R. L. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960601)77:11<2217::aid-cncr6>3.0.co;2-m · Cited by 354
α-fetoprotein: Reevaluation in hepatology
Taketa, K. (1990) · Hepatology · doi:10.1002/hep.1840120625 · Cited by 353
Cited by
Zhu, A. X., Kang, Y.-K., Yen, C.-J., Finn, R. S., Galle, P. R., Llovet, J. M., Assenat, E., Brandi, G., Pracht, M., Lim, H. Y., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30937-9 · Cited by 1,662
Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., D’Angelica, M. I., Abbott, D. E., Anaya, D. A., Anders, R., Are, C., Bachini, M., Borad, M., Brown, D., Burgoyne, A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0022 · Cited by 1,003
Zhu, A. X., Park, J. O., Ryoo, B.-Y., Yen, C.-J., Poon, R., Pastorelli, D., Blanc, J.-F., Chung, H. C., Baron, A. D., Pfiffer, T. E. F., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00050-9 · Cited by 846
The diagnosis and treatment of hepatocellular carcinoma
Hartke, J., Johnson, M., & Ghabril, M. (2017) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2016.12.011 · Cited by 670
Biology and significance of alpha-fetoprotein in hepatocellular carcinoma
Galle, P. R., Foerster, F., Kudo, M., Chan, S. L., Llovet, J. M., Qin, S., Schelman, W. R., Chintharlapalli, S., Abada, P. B., Sherman, M., et al. (2019) · Liver International · doi:10.1111/liv.14223 · Cited by 597
Metadata
- Authors
- Tangkijvanich, P., Anukulkarnkusol, N., Suwangool, P., Lertmaharit, S., Hanvivatvong, O., Kullavanijaya, P., & Poovorawan, Y.
- Venue
- Journal of Clinical Gastroenterology
- Published
- 2000-12
- Volume
- 31
- Issue
- 4
- Pages
- 302-308
- ISSN
- 0192-0790 (ISSN-L)
- OpenAlex
- W2030209959
- Cited by
- 298
- References
- 26
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Characteristics and Prognosis of Hepatocellular Carcinoma: Analysis Based on Serum Alpha-fetoprotein Levels. https://app.cochat.ai/papers/10.1097/00004836-200012000-00007
- The paper
- Tangkijvanich, P., Anukulkarnkusol, N., Suwangool, P., Lertmaharit, S., Hanvivatvong, O., Kullavanijaya, P., & Poovorawan, Y. (2000). Clinical Characteristics and Prognosis of Hepatocellular Carcinoma: Analysis Based on Serum Alpha-fetoprotein Levels. Journal of Clinical Gastroenterology. https://doi.org/10.1097/00004836-200012000-00007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.